Geoff Meacham, an analyst from Citi, maintained the Hold rating on Biogen. The associated price target remains the same with $215.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Geoff Meacham has given his Hold rating due to a combination of factors related to Biogen’s latest developments and overall outlook. While the early FDA approval of the high-dose Spinraza regimen confirms strong efficacy and a safety profile consistent with the standard dose, it largely met prior expectations and does not significantly change the company’s short-term trajectory.
He views Biogen’s investment case as still primarily driven by Alzheimer’s drug Leqembi execution and ongoing erosion in the multiple sclerosis portfolio, with Spinraza HD serving more as a stabilizing force than a major growth engine. Forecasts that 2026 Spinraza revenue will modestly decline despite the new high-dose approval underscore limited upside, leading Meacham to maintain a Neutral stance and a $215 target price.
BIIB’s price has also changed moderately for the past six months – from $140.080 to $187.570, which is a 33.90% increase.